APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Hematology

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Hematology Market Outlook and Growth Opportunities 2026

22 December 2025191 pages

Choose your research edition.

Industry ResearchDrugs for Hematology Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Hematology Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Drugs for Hematology Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Hematology Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Hematology Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Drugs for Hematology market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs for Hematology is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for Hematology is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Hematology is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs for Hematology market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs for Hematology market include Takeda, Sobi, Johnson & Johnson, Novartis, Roche, Pfizer, GSK, AbbVie and Sanof, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Drugs for Hematology market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Hematology and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Hematology sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for Hematology market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for Hematology Segment by Company

Takeda

Sobi

Johnson & Johnson

Novartis

Roche

Pfizer

GSK

AbbVie

Sanof

Bristol-Myers Squibb

Drugs for Hematology Segment by Type

OTC

Rx Drugs

Drugs for Hematology Segment by Application

Hospital

Drugs Store

Other

Drugs for Hematology Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for Hematology status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Drugs for Hematology market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Hematology significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Hematology competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Hematology market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Hematology and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Hematology.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for Hematology market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Hematology industry.

Chapter 3: Detailed analysis of Drugs for Hematology manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Drugs for Hematology in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Drugs for Hematology in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Hematology Industry Trends Table 2. Drugs for Hematology Industry Drivers Table 3. Drugs for Hematology Industry Opportunities and Challenges Table 4. Drugs for Hematology Industry Restraints Table 5. Global Drugs for Hematology Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Hematology Revenue Share by Company (2021-2026) Table 7. Global Drugs for Hematology Sales Volume by Company (k units) & (2021-2026) Table 8. Global Drugs for Hematology Sales Volume Share by Company (2021-2026) Table 9. Global Drugs for Hematology Average Price (US$/unit) of Company (2021-2026) Table 10. Global Drugs for Hematology Company Ranking, (2024-2026) & (USD Million) Table 11. Global Drugs for Hematology Key Company Manufacturing Base & Headquarters Table 12. Global Drugs for Hematology Company, Product Type & Application Table 13. Global Drugs for Hematology Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for Hematology by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of OTC Table 18. Significant Companies of Rx Drugs Table 19. Global Drugs for Hematology Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Drugs for Hematology Sales Volume by Type (2021-2026) & (k units) Table 21. Global Drugs for Hematology Sales Volume by Type (2027-2032) & (k units) Table 22. Global Drugs for Hematology Sales Volume Share by Type (2021-2026) Table 23. Global Drugs for Hematology Sales Volume Share by Type (2027-2032) Table 24. Global Drugs for Hematology Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Drugs for Hematology Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Drugs for Hematology Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Drugs for Hematology Sales Value Share by Type (2021-2026) Table 28. Global Drugs for Hematology Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Drugs Store Table 31. Significant Companies of Other Table 32. Global Drugs for Hematology Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Drugs for Hematology Sales Volume by Application (2021-2026) & (k units) Table 34. Global Drugs for Hematology Sales Volume by Application (2027-2032) & (k units) Table 35. Global Drugs for Hematology Sales Volume Share by Application (2021-2026) Table 36. Global Drugs for Hematology Sales Volume Share by Application (2027-2032) Table 37. Global Drugs for Hematology Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Drugs for Hematology Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Drugs for Hematology Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Drugs for Hematology Sales Value Share by Application (2021-2026) Table 41. Global Drugs for Hematology Sales Value Share by Application (2027-2032) Table 42. Global Drugs for Hematology Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Drugs for Hematology Sales by Region (2021-2026) & (k units) Table 44. Global Drugs for Hematology Sales Market Share by Region (2021-2026) Table 45. Global Drugs for Hematology Sales by Region (2027-2032) & (k units) Table 46. Global Drugs for Hematology Sales Market Share by Region (2027-2032) Table 47. Global Drugs for Hematology Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Drugs for Hematology Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Drugs for Hematology Sales Value Share by Region (2021-2026) Table 50. Global Drugs for Hematology Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Drugs for Hematology Sales Value Share by Region (2027-2032) Table 52. Global Drugs for Hematology Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Drugs for Hematology Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Drugs for Hematology Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Drugs for Hematology Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Drugs for Hematology Sales by Country (2021-2026) & (k units) Table 57. Global Drugs for Hematology Sales Market Share by Country (2021-2026) Table 58. Global Drugs for Hematology Sales by Country (2027-2032) & (k units) Table 59. Global Drugs for Hematology Sales Market Share by Country (2027-2032) Table 60. Global Drugs for Hematology Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Drugs for Hematology Sales Value Market Share by Country (2021-2026) Table 62. Global Drugs for Hematology Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Drugs for Hematology Sales Value Market Share by Country (2027-2032) Table 64. Takeda Company Information Table 65. Takeda Business Overview Table 66. Takeda Drugs for Hematology Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Takeda Drugs for Hematology Product Portfolio Table 68. Takeda Recent Development Table 69. Sobi Company Information Table 70. Sobi Business Overview Table 71. Sobi Drugs for Hematology Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Sobi Drugs for Hematology Product Portfolio Table 73. Sobi Recent Development Table 74. Johnson & Johnson Company Information Table 75. Johnson & Johnson Business Overview Table 76. Johnson & Johnson Drugs for Hematology Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Johnson & Johnson Drugs for Hematology Product Portfolio Table 78. Johnson & Johnson Recent Development Table 79. Novartis Company Information Table 80. Novartis Business Overview Table 81. Novartis Drugs for Hematology Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Novartis Drugs for Hematology Product Portfolio Table 83. Novartis Recent Development Table 84. Roche Company Information Table 85. Roche Business Overview Table 86. Roche Drugs for Hematology Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Roche Drugs for Hematology Product Portfolio Table 88. Roche Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer Drugs for Hematology Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Pfizer Drugs for Hematology Product Portfolio Table 93. Pfizer Recent Development Table 94. GSK Company Information Table 95. GSK Business Overview Table 96. GSK Drugs for Hematology Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. GSK Drugs for Hematology Product Portfolio Table 98. GSK Recent Development Table 99. AbbVie Company Information Table 100. AbbVie Business Overview Table 101. AbbVie Drugs for Hematology Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. AbbVie Drugs for Hematology Product Portfolio Table 103. AbbVie Recent Development Table 104. Sanof Company Information Table 105. Sanof Business Overview Table 106. Sanof Drugs for Hematology Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Sanof Drugs for Hematology Product Portfolio Table 108. Sanof Recent Development Table 109. Bristol-Myers Squibb Company Information Table 110. Bristol-Myers Squibb Business Overview Table 111. Bristol-Myers Squibb Drugs for Hematology Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Bristol-Myers Squibb Drugs for Hematology Product Portfolio Table 113. Bristol-Myers Squibb Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Drugs for Hematology Distributors List Table 117. Drugs for Hematology Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Drugs for Hematology Product Image Figure 2. Global Drugs for Hematology Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Hematology Sales Value (2021-2032) & (US$ Million) Figure 4. Global Drugs for Hematology Sales (2021-2032) & (k units) Figure 5. Global Drugs for Hematology Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Drugs for Hematology Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. OTC Image Figure 10. Rx Drugs Image Figure 11. Global Drugs for Hematology Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Drugs for Hematology Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Drugs for Hematology Sales Volume Share by Type (2021-2032) Figure 14. Global Drugs for Hematology Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Drugs for Hematology Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Drugs for Hematology Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Drugs Store Image Figure 19. Other Image Figure 20. Global Drugs for Hematology Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Drugs for Hematology Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Drugs for Hematology Sales Volume Share by Application (2021-2032) Figure 23. Global Drugs for Hematology Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Drugs for Hematology Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Drugs for Hematology Sales Value Share by Application (2021-2032) Figure 26. Global Drugs for Hematology Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Drugs for Hematology Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Drugs for Hematology Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Drugs for Hematology Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Drugs for Hematology Sales Value (2021-2032) & (US$ Million) Figure 31. North America Drugs for Hematology Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Drugs for Hematology Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Drugs for Hematology Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Drugs for Hematology Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Drugs for Hematology Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Drugs for Hematology Sales Value (2021-2032) & (US$ Million) Figure 37. South America Drugs for Hematology Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Drugs for Hematology Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Drugs for Hematology Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Drugs for Hematology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Drugs for Hematology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Drugs for Hematology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Drugs for Hematology Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Drugs for Hematology Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • OTC
  • Rx Drugs
Applications
  • Hospital
  • Drugs Store
  • Other
Companies covered
  • Takeda
  • Sobi
  • Johnson & Johnson
  • Novartis
  • Roche
  • Pfizer
  • GSK
  • AbbVie
  • Sanof
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for Hematology Sales Value (2021-2032)
  4. 1.2.2 Global Drugs for Hematology Sales Volume (2021-2032)
  5. 1.2.3 Global Drugs for Hematology Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Drugs for Hematology Market Dynamics
  1. 2.1 Drugs for Hematology Industry Trends
  2. 2.2 Drugs for Hematology Industry Drivers
  3. 2.3 Drugs for Hematology Industry Opportunities and Challenges
  4. 2.4 Drugs for Hematology Industry Restraints
3 Drugs for Hematology Market by Company
  1. 3.1 Global Drugs for Hematology Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Hematology Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Hematology Sales Volume by Company (2021-2026)
  4. 3.4 Global Drugs for Hematology Average Price by Company (2021-2026)
  5. 3.5 Global Drugs for Hematology Company Ranking (2024-2026)
  6. 3.6 Global Drugs for Hematology Company Manufacturing Base and Headquarters
  7. 3.7 Global Drugs for Hematology Company Product Type and Application
  8. 3.8 Global Drugs for Hematology Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Drugs for Hematology Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Drugs for Hematology Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Drugs for Hematology Market by Type
  1. 4.1 Drugs for Hematology Type Introduction
  2. 4.1.1 OTC
  3. 4.1.2 Rx Drugs
  4. 4.2 Global Drugs for Hematology Sales Volume by Type
  5. 4.2.1 Global Drugs for Hematology Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Drugs for Hematology Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Drugs for Hematology Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Drugs for Hematology Sales Value by Type
  9. 4.3.1 Global Drugs for Hematology Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Drugs for Hematology Sales Value by Type (2021-2032)
  11. 4.3.3 Global Drugs for Hematology Sales Value Share by Type (2021-2032)
5 Drugs for Hematology Market by Application
  1. 5.1 Drugs for Hematology Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drugs Store
  4. 5.1.3 Other
  5. 5.2 Global Drugs for Hematology Sales Volume by Application
  6. 5.2.1 Global Drugs for Hematology Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for Hematology Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Drugs for Hematology Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Drugs for Hematology Sales Value by Application
  10. 5.3.1 Global Drugs for Hematology Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Drugs for Hematology Sales Value by Application (2021-2032)
  12. 5.3.3 Global Drugs for Hematology Sales Value Share by Application (2021-2032)
6 Drugs for Hematology Regional Sales and Value Analysis
  1. 6.1 Global Drugs for Hematology Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Hematology Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for Hematology Sales by Region: 2021-2026
  4. 6.2.2 Global Drugs for Hematology Sales by Region (2027-2032)
  5. 6.3 Global Drugs for Hematology Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Drugs for Hematology Sales Value by Region (2021-2032)
  7. 6.4.1 Global Drugs for Hematology Sales Value by Region: 2021-2026
  8. 6.4.2 Global Drugs for Hematology Sales Value by Region (2027-2032)
  9. 6.5 Global Drugs for Hematology Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Drugs for Hematology Sales Value (2021-2032)
  12. 6.6.2 North America Drugs for Hematology Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Drugs for Hematology Sales Value (2021-2032)
  15. 6.7.2 Europe Drugs for Hematology Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Drugs for Hematology Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Drugs for Hematology Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Drugs for Hematology Sales Value (2021-2032)
  21. 6.9.2 South America Drugs for Hematology Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Drugs for Hematology Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Drugs for Hematology Sales Value Share by Country, 2025 VS 2032
7 Drugs for Hematology Country-level Sales and Value Analysis
  1. 7.1 Global Drugs for Hematology Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Hematology Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Drugs for Hematology Sales by Country (2021-2032)
  4. 7.3.1 Global Drugs for Hematology Sales by Country (2021-2026)
  5. 7.3.2 Global Drugs for Hematology Sales by Country (2027-2032)
  6. 7.4 Global Drugs for Hematology Sales Value by Country (2021-2032)
  7. 7.4.1 Global Drugs for Hematology Sales Value by Country (2021-2026)
  8. 7.4.2 Global Drugs for Hematology Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Drugs for Hematology Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Drugs for Hematology Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Drugs for Hematology Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Drugs for Hematology Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Drugs for Hematology Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Drugs for Hematology Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Drugs for Hematology Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Drugs for Hematology Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Drugs for Hematology Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Drugs for Hematology Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Drugs for Hematology Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Drugs for Hematology Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Drugs for Hematology Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Drugs for Hematology Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Drugs for Hematology Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Drugs for Hematology Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Drugs for Hematology Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Drugs for Hematology Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Drugs for Hematology Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Drugs for Hematology Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Drugs for Hematology Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Drugs for Hematology Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Drugs for Hematology Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Drugs for Hematology Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Drugs for Hematology Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Drugs for Hematology Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Drugs for Hematology Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Drugs for Hematology Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Drugs for Hematology Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Drugs for Hematology Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Drugs for Hematology Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Drugs for Hematology Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Sobi
  8. 8.2.1 Sobi Company Information
  9. 8.2.2 Sobi Business Overview
  10. 8.2.3 Sobi Drugs for Hematology Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sobi Drugs for Hematology Product Portfolio
  12. 8.2.5 Sobi Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Drugs for Hematology Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Drugs for Hematology Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Drugs for Hematology Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Drugs for Hematology Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Drugs for Hematology Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Roche Drugs for Hematology Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Drugs for Hematology Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Drugs for Hematology Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 GSK
  38. 8.7.1 GSK Company Information
  39. 8.7.2 GSK Business Overview
  40. 8.7.3 GSK Drugs for Hematology Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GSK Drugs for Hematology Product Portfolio
  42. 8.7.5 GSK Recent Developments
  43. 8.8 AbbVie
  44. 8.8.1 AbbVie Company Information
  45. 8.8.2 AbbVie Business Overview
  46. 8.8.3 AbbVie Drugs for Hematology Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 AbbVie Drugs for Hematology Product Portfolio
  48. 8.8.5 AbbVie Recent Developments
  49. 8.9 Sanof
  50. 8.9.1 Sanof Company Information
  51. 8.9.2 Sanof Business Overview
  52. 8.9.3 Sanof Drugs for Hematology Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sanof Drugs for Hematology Product Portfolio
  54. 8.9.5 Sanof Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb Drugs for Hematology Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb Drugs for Hematology Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for Hematology Value Chain Analysis
  2. 9.1.1 Drugs for Hematology Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for Hematology Sales Mode & Process
  6. 9.2 Drugs for Hematology Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for Hematology Distributors
  9. 9.2.3 Drugs for Hematology Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst